Universita Degli Studi Del Piemonte Orientale "amedeo Avogadro"

Antalgenics, S.l.

Universita Degli Studi Del Piemonte Orientale

Universtà Degli Studi Di Torino

Kither Biotech Srl

Tracey Pirali

Armando Genazzani

Antonio Vicente Ferrer Montiel

Emilio Hirsch

Isabel Devesa Giner

Asia Fernandez Carvajal

Elisa Ciraolo

Gian Cesare Tron

Giovanni Sorba

Ubaldina Galli

Alberto Massarotti

Beatrice Riva

Silvio Aprile

Celia Cordero Sanchez

Marta Serafini

Ambra Grolla

The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R, R, Rand Rare independently selected from H, (C-C)alkyl, unsaturated (C-C)hydrocarbon, and (C-C)cycloalkyl, being these groups optionally substituted; Ris hydrogen or halogen; Ris selected from H, (C-C)alkyl, unsaturated (C-C)hydrocarbon, (C-C)cycloalkyl, (C-C)aryl, and (C-C)heteroaryl, being these groups optionally substituted; and Ris selected from (C-C)alkyl, unsaturated (C-C)hydrocarbon, (C-C)aryl, and (C-C)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications. 

TRPV1 modulator compounds

Compounds of Formula (I) able to modulate Store Operated Calcium Entry (SOCE). The disclosure also relates to the use of compounds of formula (I) for treatment of pathological conditions in which SOCE modulation might be beneficial, such as neglecting disorders linked to loss- or gain-of-function STIM1/Orai1 mutations, allergic disorders, pain, inflammatory diseases, autoimmune diseases or disorders, cancer and other proliferative diseases, neurodegenerative disorders, myelodysplastic syndromes, haematological diseases, cardiovascular diseases, degenerative diseases of the musculoskeletal system, liver diseases and disorders, kidney diseases, type I diabetes, graft rejection, graft-versus-host disease, allogeneic or xenogeneic transplantation, thyroiditis and viral infections.

Modulators of SOCE, compositions, and uses thereof

Compounds of Formula (I): able to inhibit kinase activity, in particular Phosphatidylinositol 3-Kinases activity. The disclosure also relates to the use of compounds of Formula (I) for treatment of pathological conditions associated to alterations in Phosphatidylinositol 3-Kinases activity. 

Quinolin-4 (1H)-one derivatives as inhibitors of phosphatidylinositol 3-kinases

Growing community of inventors

Novara, Italy

Tracey Pirali